Exent Corp
Exent Corp. focuses on developing, promoting, and executing integrated smart-home systems and solutions in the People's Republic of China. It was engages in the manufacturing and sales of drywall steel studs which were used in new developments, commercial, and residential construction and in home improvement, remodeling and repair work in Kyrgyzstan. The company was founded in 2017 and is based i… Read more
Exent Corp (EXNN) - Net Assets
Latest net assets as of September 2021: $-6.24K USD
Based on the latest financial reports, Exent Corp (EXNN) has net assets worth $-6.24K USD as of September 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($0.00) and total liabilities ($6.24K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.24K |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Exent Corp - Net Assets Trend (2017–2020)
This chart illustrates how Exent Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Exent Corp (2017–2020)
The table below shows the annual net assets of Exent Corp from 2017 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | $-9.34K | +51.19% |
| 2019-12-31 | $-19.14K | -977.32% |
| 2018-12-31 | $-1.78K | -239.26% |
| 2017-12-31 | $1.28K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Exent Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11647500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.03K | % |
| Other Components | $105.33K | % |
| Total Equity | $-9.34K | 100.00% |
Exent Corp Competitors by Market Cap
The table below lists competitors of Exent Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Albion Resources Ltd
AU:ALB
|
$2.11 Million |
|
America Great Health
PINK:AAGH
|
$2.12 Million |
|
HBM Healthcare Investments
SW:HBMN
|
$2.12 Million |
|
Viji Finance Limited
NSE:VIJIFIN
|
$2.12 Million |
|
Indo Pureco Pratama Tbk PT
JK:IPPE
|
$2.11 Million |
|
Norse Gold Corp
V:VKG-H
|
$2.11 Million |
|
People's Garment Public Company Limited
BK:PG
|
$2.11 Million |
|
DAYTHREE DIGITAL BERHAD
KLSE:0281
|
$2.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Exent Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from -19,144 to -9,344, a change of 9,800.
- Net loss of 69,705 reduced equity.
- Other comprehensive income increased equity by 1,527.
- Other factors increased equity by 77,978.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-69.70K | -745.99% |
| Other Comprehensive Income | $1.53K | +16.34% |
| Other Changes | $77.98K | +834.52% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Exent Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.00 | $4.01 | x |
| 2018-12-31 | $0.00 | $4.01 | x |
| 2019-12-31 | $-0.01 | $4.01 | x |
| 2020-12-31 | $0.00 | $4.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Exent Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-4.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -17.55% | 0.00% | 0.00x | 1.18x | $-351.60 |
| 2018 | 0.00% | -338.20% | 0.36x | 0.00x | $-29.23K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.45K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-68.77K |
Industry Comparison
This section compares Exent Corp's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Exent Corp (EXNN) | $-6.24K | -17.55% | N/A | $2.11 Million |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |